Jeff Tornheim, MD, MPH

Role: 
Faculty
Assistant Professor
Jeff Tornheim, MD, MPH
Jeff Tornheim, MD, MPH, is Assistant Professor in the Division of Infectious Diseases here at Johns Hopkins University School of Medicine. His research explores the application of new diagnostic technologies to improved health outcomes in the treatment of drug resistant tuberculosis among both adult and pediatric patients in India. 

Dr. Tornheim recently completed his infectious diseases fellowship at Johns Hopkins, during which he worked with Drs. Amita Gupta, Vidya Mave, Bob Bollinger of Johns Hopkins, and with Dr. Zarir Udwadia at the Hinduja Hospital in Mumbai. His interest in clinical outcomes for underserved populations led him to practice in physician training environments in Bolivia, Peru, South Sudan, Kenya, Uganda, Rwanda, South Africa, and the United States.

Dr. Tornheim completed a clinical fellowship in infectious diseases in June 2017. Prior to that he completed residencies at Yale University in both internal medicine and pediatrics. He received an MD/MPH from Mount Sinai School of Medicine, with his thesis evaluating the impact of water policy on rates of pediatric diarrhea in Bolivia. After completing undergraduate studies in International Development and Economics at Brandeis University he moved to East Africa where he engaged in health system strengthening for returning refugees to South Sudan and worked with the Centers for Disease Control and Prevention (CDC) on the epidemiology of pneumonia and diarrhea in Western Kenya. At the same time he worked at the Bureau of TB Control for the Department of Health and Mental Hygiene and was actively engaged in the operations of an East Harlem free clinic. As a Fogarty International Clinical Scholar, he spent 2 years in rural Bolivia establishing and managing operations for a Chagas Disease treatment program.

 

Host RNA Expression for Diagnosis and Monitoring of Pediatric TB in Africa and India

Post Date: 
2018-12-13
   |   
Countries: 
   |   
Clinical Sites: 
We are leveraging the RePORT platform by including a cohort of Indian children together with South African children in a large validation study to study on changes in gene expression profiles during treatment for TB

Assessing Tuberculosis Transmission Dynamics, Drug Resistance and Recurrence Using Whole Genome Sequencing in Pune, India

Post Date: 
2018-06-12
   |   
Countries: 
Indo-JHU researchers are using combined geospatial and genotyping methods to describe TB transmission dynamics in a hyperlocal region of Pune City in Western India.

Predictors of Resistance Emergence Evaluation in Multidrug Resistant-Tuberculosis Patients on Treatment (PREEMPT Pilot Study)

Post Date: 
2018-03-20
   |   
Countries: 
   |   
Clinical Sites: 
Indo-JHU Clinical Resarch Partnership is participating with Brazilian colleagues in a 3-year effort led by Boston University to identify what contributes to TB drug resistance.

MDR-TB Free: Monitoring Adverse Effects, Utilizing Resources Optimally, Knowing Resistance Patterns, and Treatment Strategy

Post Date: 
2017-03-24
   |   
Countries: 
   |   
Clinical Sites: 
This study is also known as MDR-TB MUKT: M onitoring Adverse Effects, U tilizing Resources Optimally, K nowing Resistance Patterns, and T reatment Strategy. Purpose: To establish an observational cohort of MDR-TB cases and household contacts with accompanying biorepository at PD Hinduja National...

Multicenter Study of the Accuracy of the BD MAX MDR-TB Assay for Detection of M. tuberculosis Complex and Mutations Associated with Resistance to Rifampin or Isoniazid

Post Date: 
2017-03-01
   |   
Countries: 
   |   
Clinical Sites: 
In a multi-country study, we are assessing the accuracy of the BD MAX rapid MDR-TB assay to detect rifampin and isoniazid resistance.

Transcriptomic and Metabolomic Analysis of Microbiologically Confirmed Pediatric Tuberculosis Patients and Uninfected Household Contacts

Post Date: 
2016-09-01
   |   
Countries: 
   |   
Clinical Sites: 
This study is using stored samples from the Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH), under the Regional Prospective Observational Research for Tuberculosis (RePORT) Network, an international TB consortium. The objectives for this study are to: Assess the...

Establishing an Observational Cohort Database for Patient Care and Research at the Hinduja Hospital Chest Clinic

Post Date: 
2016-08-30
   |   
Countries: 
   |   
Clinical Sites: 
India has the largest burden of global tuberculosis (TB), accounting for one quarter of the total number of cases reported. Together with South Africa, India sees one-third of the total number of deaths from TB. Drug-resistant strains of the disease are also on the rise, with India having one of...

Whole Genome Sequencing and Trek Sensititre Testing of Stored Isolates of Drug-resistant Tuberculosis from a Clinical Cohort at Hinduja Hospital, Mumbai

Post Date: 
2016-05-02
   |   
Countries: 
   |   
Clinical Sites: 
Among HIV-positive TB patients presenting to Médecins San Frontières (MSF) clinics in Mumbai, 78% carried MDR-TB strains, with nearly half also found to have additional drug resistance. A previously published cohort of 202 patients cared for at these MSF clinics have enrolled in a cross-sectional...

Whole Genome Sequencing of Clinical Isolates from Patients with Multidrug Resistant Tuberculosis in India 

Post Date: 
2015-11-12
   |   
Countries: 
   |   
Clinical Sites: 
Comparative genomic analysis using whole genome sequencing (WGS) offers an opportunity to understand the specific mutations associated with drug resistance and the phenotypic behavior of TB. As treatment programs incorporate more molecular diagnostics such as Xpert MTB/RIF and line probe assays, it...

BWI CTU: Baltimore-Washington-India Clinical Trials Unit

Post Date: 
2007-02-02
   |   
Countries: 
   |   
Clinical Sites: 
Comprising clinical trial sites at Johns Hopkins Medicine in Baltimore, Whitman Walker Health in Washington, DC, and the BJGMC-CCGHE collaboration in Pune, India, the Baltimore-Washington-India Clinical Trials Unit (BWI-CTU) is one of only 25 international HIV/TB clinical trial sites funded by the...

Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex

Post Date: 
2019-03-18
Publication: 
Clinical Infectious Diseases
Abstract Tuberculosis is the primary infectious disease killer worldwide, with a growing threat from multidrug- resistant cases. Unfortunately, classic growth-based phenotypic drug susceptibility testing (DST) remains difficult, costly and time-consuming, while current rapid molecular testing...

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Post Date: 
2019-01-28
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
BMC Infectious Diseases
BACKGROUND: India has the world's highest tuberculosis burden, and Mumbai is particularly affected by multidrug resistant tuberculosis (MDR-TB). WHO recommends short, intensive treatment ("Short Course") for previously untreated pulmonary MDR-TB patients but does not require universal drug...

Atypical mycobacterial infections following plastic surgery procedures abroad: a multidisciplinary algorithm for diagnosis and treatment

Post Date: 
2018-12-28
Abstract: Medical tourism has become increasingly popular in recent years. The most commonly sought procedures are cosmetic. The recent rise in medical tourism has been mirrored by an increase in the incidence of M. abscessus infections, atypical mycobacteria ubiquitous in aquatic environments...

Multiplex-PCR to detect pAmpC β-lactamases among Enterobacteriaceae at a tertiary care laboratory in Mumbai, India

Post Date: 
2018-12-13
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Microbiology
Drug-resistance due to AmpC β-lactamases represents a growing problem worldwide. In this study, a previously collected sample of 108 cefoxitin-resistant clinical isolates was assessed for AmpC β-lactamase production through routine phenotypic testing and double-disc cefoxitin/cloxcallin (DD-CC),...

The global landscape of tuberculosis therapeutics

Post Date: 
2018-11-07
Publication: 
Annual Review of Medicine
Abstract Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important...

Challenges of TB and co-treatment: updates and insights

Post Date: 
2018-08-04
Publication: 
Current Opinion in HIV and AIDS
PURPOSE OF REVIEW: In the past few years, tuberculosis (TB) has overtaken HIV as the infectious disease with the highest global mortality. Successful management of this syndemic will require improved diagnostic tests, shorter preventive therapies, and more effective treatments, particularly in...

Pyrosequencing to resolve discrepant Xpert MTB/RIF and Mycobacterial Growth Indicator Tube 960

Post Date: 
2018-03-26
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Lung India
Lung India: Indo-JHU researchers find that pyrosequencing can clear up discrepancies about drug resistance in TB.

Of testing and treatment: Implications of implementing new regimens for multidrug-resistant tuberculosis

Post Date: 
2017-10-01
Publication: 
Clinical Infectious Diseases
A novel, shorter-course regimen for treating multidrug-resistant (MDR) tuberculosis was recently recommended by the World Health Organization. However, the most appropriate use of drug susceptibility testing (DST) to support this regimen is less clear. Implementing countries must therefore often...

Drug-resistant tuberculosis in 2017: at a crossroads

Post Date: 
2017-03-15
Publication: 
Lancet Respiratory Medicine
In The Lancet Respiratory Medicine, Dheda and colleagues present one of the most comprehensive pictures to date of the global epidemic of drug-resistant tuberculosis. This comes at a time of increasing awareness of antimicrobial resistance as a global threat, and Mycobacterium tuberculosis has had...

Tuberculosis associated with HIV infection

Post Date: 
2017-01-15
Publication: 
Microbiology Spectrum
Abstract Tuberculosis (TB) has recently surpassed HIV as the primary infectious disease killer worldwide, but the two diseases continue to display lethal synergy. The burden of TB is disproportionately borne by people living with HIV, particularly where HIV and poverty coexist. The impact of these...

Bedaquiline

Post Date: 
2017-01-01
Publication: 
Kucers’ the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, and Antiviral Drugs, 7th Edition
Section II, Antibiotics: Part 12 Anti-tuberculosis drugs.

Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system

Post Date: 
2016-06-13
Publication: 
Neurology, Neuroimmunology and Neuroinflammation
OBJECTIVE: To determine the feasibility of next-generation sequencing (NGS) microbiome approaches in the diagnosis of infectious disorders in brain or spinal cord biopsies in patients with suspected CNS infections. METHODS: In a prospective pilot study, we applied NGS in combination with a new...

Quality of Life Among MDR-TB Patients from the Public Sector in Mumbai

Post Date: 
2019-02-04
   |   
Countries: 
   |   
Clinical Sites: 
Gajjar IN , Udwadia ZF, Kishore G, Karane M, Sayed S, Sawant N, Chawla PK, Rodrigues C, Ashavaid TK, Shivakumar SVBY, Gupta A, Tornheim JA. Quality of Life Among MDR-TB Patients from the Public Sector in Mumbai. 8th Annual Regional Prospective Observational Research for Tuberculosis (RePORT) India...

Whole Genome Sequencing of Mycobacterium Tuberculosis Directly from Clinical Samples Accurately Identifies Drug Resistance

Post Date: 
2019-02-04
   |   
Countries: 
   |   
Clinical Sites: 
Kambli P , Tornheim JA, Soundararajan L, Priyadarshini S, Gupta R, Ramprasad VL, Gupta A, Rodrigues C. Whole Genome Sequencing of Mycobacterium Tuberculosis Directly from Clinical Samples Accurately Identifies Drug Resistance. 8th Annual Regional Prospective Observational Research for Tuberculosis...

Impact of Standard or Increased Moxifloxacin Dose Among MDR-TB Patients in Mumbai with Low-Level Resistance

Post Date: 
2019-02-04
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim JA , Udwadia ZF, Porwal S, Kishore G, Gajjar I, Karane M, Shivakumar SVBY, Rodrigues C, Gupta A. Impact of Standard or Increased Moxifloxacin Dose Among MDR-TB Patients in Mumbai with Low-Level Resistance. 8th Annual Regional Prospective Observational Research for Tuberculosis (RePORT)...

Linezolid Resistance in Mycobacterium Tuberculosis Isolates at a Tertiary Care Center in Mumbai, India, by Whole Genome Sequencing

Post Date: 
2019-02-04
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim JA , Diricks M, Katrien DB, Sadani M, Shetty A, Rodrigues C. Linezolid Resistance in Mycobacterium Tuberculosis Isolates at a Tertiary Care Center in Mumbai, India, by Whole Genome Sequencing. RePORT India 2019 Joint Leadership Meeting. Chennai, India. February 4-6, 2019.

Determination of Plasma Clofazimine Levels by Liquid Chromatography-Mass Spectrometry

Post Date: 
2019-02-04
   |   
Countries: 
   |   
Clinical Sites: 
Chawla PK , Lokhande RV, Naik PR, Dherai AJ, Udwadia ZF, Mahashur AA, Pinto L, Soman R, Rodrigues C, Gupta A, Tornheim JA, Martinson N, Variava E, Weisner L, Joubert A, Ashavaid TF. Determination of Plasma Clofazimine Levels by Liquid Chromatography-Mass Spectrometry. 8th Annual Regional...

Determination of Serum Linezolid Levels by HPLC

Post Date: 
2019-02-04
   |   
Countries: 
   |   
Clinical Sites: 
Chawla PK , Lokhande RV, NaiF PR, Dherai AJ, Udwadia ZF, Mahashur AA, Soman R, Rodrigues C, Gupta A, Tornheim JA, Ashavaid TK. Determination of Serum Linezolid Levels by HPLC. 8th Annual Regional Prospective Observational Research for Tuberculosis (RePORT) India Joint Leadership meeting – ‘’...

Mental Health and TB: High Prevalence of Depression among Drug-resistant TB Patients not Associated with Cycloserine

Post Date: 
2019-02-04
   |   
Countries: 
   |   
Clinical Sites: 
Shivakumar SVBY , Tornheim JA, Gajjar I, Porwal S, Kishore G, Karane M, Sayed S, Chawla PK, Rodrigues C, Ashavaid TK, Gupta A, Udwadia ZF. Mental Health and TB: High prevalence of depression among drug-resistant TB patients not associated with cycloserine. 8th Annual Regional Prospective...

How can we translate next generation sequencing data to shorten anti-tuberculosis treatment?

Post Date: 
2018-10-23
Tornheim J. How can we translate next generation sequencing data to shorten anti-tuberculosis treatment? TBScience 2 Parallel session on reducing transmission: what is the scientific basis behind for the reduction of transmission and the initiation of appropriate treatment? 49th Annual Union World...

Linezolid Experience Among MDR-TB Patients in Mumbai

Post Date: 
2018-03-16
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim J. Linezolid Experience Among MDR-TB Patients in Mumbai. 2018 Research Retreat, Johns Hopkins Department of Medicine. Baltimore, MD. 2018.

Linezolid Experience Among MDR-TB Patients in Mumbai

Post Date: 
2018-02-15
   |   
Countries: 
Tornheim JA, Ganatra S, Deluca A, Banka R, Rodrigues C, Gupta A, Udwadia ZF. Linezolid Experience Among MDR-TB Patients in Mumbai. RePORT India Annual Meeting. New Delhi, India.

Drug Susceptibility of Rifampin-resistant Tuberculosis using Whole Genome Sequencing to Identify Genes of Interest in Pune, India

Post Date: 
2018-02-15
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim JA, Madugundu AK, Pradhan N, Bharadwaj R, Mave V, Golub J, Pandey A, Gupta A. Drug Susceptibility of Rifampin-resistant Tuberculosis using Whole Genome Sequencing to Identify Genes of Interest in Pune, India. RePORT India Annual Meeting. New Delhi, India.

Drug Susceptibility of Rifampin-resistant Tuberculosis using Whole Genome Sequencing to Identify Genes of Interest in Pune, India

Post Date: 
2017-10-12
   |   
Clinical Sites: 
Tornheim JA , Madugundu AK, Pradhan N, Bharadwaj R, Mave V, Golub J, Pandey A, Gupta A. Drug Susceptibility of Rifampin-resistant Tuberculosis using Whole Genome Sequencing to Identify Genes of Interest in Pune, India. 48th Annual Union World Conference of Lung Health. Guadalajara, Mexico.

Linezolid Experience among MDRTB Patients in Mumbai

Post Date: 
2017-09-13
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim J, Ganatra S, Deluca A, Banka R, Rodrigues C, Gupta A, Udwadia Z. Poster Presentation. Linezolid Experience among MDRTB Patients in Mumbai. ERS International Congress. European Respiratory Society. Milan, Italy.

Gene Expression Profiles of Pediatric Tuberculosis Patients and Exposed Controls from India

Post Date: 
2017-09-13
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim JA , Paradkar M, Madugundu A, Gupte N, Kulkarni V, Sreenivasamurthy S, Raja R, Pradhan N, Shivakumar SVBY, Valvi C, Kohli R, Chandrasekaran P, Mave V, Pandey A, Gupta A. Gene Expression Profiles of Pediatric Tuberculosis Patients and Exposed Controls from India. RePORT International...

CTRIUMPh Pediatric Biomarker Substudy

Post Date: 
2017-05-30
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim J . Paradkar M. CTRIUMPh Pediatric Biomarker Substudy. 2017 IMPAACT Annual Meeting. Washington, DC. 2017.

It Simply Won’t Work Here – Few Eligible for the Newly Recommended Short Course MDR-TB Regimen in a Mumbai Private Clinic

Post Date: 
2017-05-21
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim J , DeLuca A, Ganatra S, Radhika B, Gupta A, Udwadia Z. It Simply Won’t Work Here – Few Eligible for the Newly Recommended Short Course MDR-TB Regimen in a Mumbai Private Clinic. American Thoracic Society 2017 International Conference. Washington, DC. 2017.

Communicating Whole Genome Sequencing Results for Tuberculosis: What Does It Mean and Who Needs to Know?

Post Date: 
2017-04-25
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim, J. Communicating Whole Genome Sequencing Results for Tuberculosis: What Does It Mean and Who Needs to Know? Foundation for Medical Research. Mumbai, India.

What are We Trying to Say Here? Standardizing Next Generation Sequencing Reports for Tuberculosis

Post Date: 
2017-03-30
Tornheim, J. What are We Trying to Say Here? Standardizing Next Generation Sequencing Reports for Tuberculosis. 2017 Critical Path to TB Drug Regimens Annual Workshop. Washington, DC. 2017.

Impact of Drug Susceptibility Testing on Drug Choice in a Tuberculosis Cohort with High Rates of Drug Resistance from the Private Sector in Mumbai

Post Date: 
2017-02-03
   |   
Countries: 
   |   
Clinical Sites: 
Tornheim JA , Ganatra S, DeLuca A, Banka R, Gupta A, Udwadia ZF. Impact of Drug Susceptibility Testing on Drug Choice in a Tuberculosis Cohort with High Rates of Drug Resistance from the Private Sector in Mumbai. 6th Annual Regional Prospective Observational Research for Tuberculosis (RePORT) India...

Descriptive Baseline Characteristics, Treatment Outcomes and Biorepository of Pediatric TB Cases in CTRIUMPh-RePORT India Prospective Cohort

Post Date: 
2017-02-03
   |   
Countries: 
   |   
Clinical Sites: 
Paradkar M , Kavitha D, Shiva Kumar SVBY, Khadse S, Khwaja S, Hari K, Rani N, Thiruvengadam K, Gupte N, Raskar S, Jain D, Suryavanshi S, Kohli R, Kulkarni V, Pradhan N, Sathyamurthi B, Tornheim J, Gupte A, DeLuca A, Mave V, Chandrasekaran P, Gupta A for the CTRIUMPH Study Team. Descriptive Baseline...

Pages

Pranay Vishwanath

Baltimore, Maryland
Pranay-Vishwanath
Pranay Vishwanath is a master's candidate in the field of Bioinformatics at Johns Hopkins University in Baltimore, and anticipated to graduate in Fall 2018. He is working with Drs. Amita Gupta and Jeffrey Tornheim, and is focusing on organization of data and generation/streamlining of bioinformatic pipelines for analysis of TB drug resistance assays. He received a bachelor's degree in Biotechnology at the Hong Kong University of Science & Technology in 2016.

Tornheim Receives W. Leigh Thompson Excellence in Research Award

Post Date: 
2018-03-21
Dr. Jeffrey Tornheim
Jeff Tornheim's research on drug-resistant tuberculosis in India garners high honors from Johns Hopkins Department of Medicine.

Tornheim Promoted to Assistant Professor

Post Date: 
2017-08-31
His research explores whether 2 MDR-TB drug susceptibility tests using WGS & MIC can yield options for individualized treament.

CCGHE at ATS 2017

Post Date: 
2017-05-08
Abstract presentations from the American Thoracic Society International Conference in Washington, DC

Advancing Global TB Research through RePORT

Post Date: 
2016-02-29
Regional Prospective Observational Research for Tuberculosis (RePORT) International is a large, international tuberculosis research effort being undertaken by 4 regional consortia: RePORT Brazil, RePORT South Africa, RePORT Indonesia, and RePORT India. While each region collects and maintains its...